Show simple item record

dc.contributor.authorLevac, Brendanen
dc.date2014-08-29 13:24:46.088
dc.date2014-09-04 09:14:38.879
dc.date2014-09-13 15:06:38.345
dc.date.accessioned2014-09-13T19:19:43Z
dc.date.available2014-09-13T19:19:43Z
dc.date.issued2014-09-13
dc.identifier.urihttp://hdl.handle.net/1974/12447
dc.descriptionThesis (Master, Kinesiology & Health Studies) -- Queen's University, 2014-09-13 15:06:38.345en
dc.description.abstractPhosphate is a mineral component of the human diet that is essential for life. However, elevated blood phosphate levels are associated with cardiovascular disease and death in the general population. The mechanisms through which phosphate may be detrimental to cardiovascular health remain unclear, however there is emerging evidence that suggests phosphate may impair the function of human arteries. The purpose of this study was to investigate whether a single phosphate supplement affects the ability of the brachial artery to dilate in response to: a) increases in blood flow (flow-mediated dilation, FMD), b) a drug that causes dilation (GTN), or c) both FMD and GTN. 17 healthy male participants (22.9 ±3.07 years old) were exposed to phosphate (PHOS) and placebo (PLAC) conditions over two experimental days (one each visit) in a within-subjects, randomized, double-blinded, placebo-controlled trial. Subjects drank a liquid containing 1200 mg of phosphorus or a placebo. FMD tests were performed pre- and 20 min, 60 min and 120 min post-supplement or placebo ingestion by a standard procedure involving the occlusion of blood flow to the forearm (reactive hyperemia). Blood phosphate concentrations were significantly greater in PHOS vs. PLAC, but did not increase differently between the two groups. Blood phosphate concentrations were significantly greater 60 min vs. 20 min post-supplement in both conditions. Phosphate excretion increased 315% in the PHOS vs. PLAC condition, indicating that the kidney rapidly removed phosphate from the blood. There was no difference in FMD between PHOS and PLAC conditions at any post-supplement time point. There was no effect of PHOS on the GTN tests. These findings indicate that a single phosphate supplement did not impair brachial artery dilation in response to increases in blood flow or the administration of a drug that induces dilation. Also, the phosphate supplement did not substantially increase phosphate concentrations in the blood likely due to a large excretion of phosphate by the kidneys. Further research is needed to better understand how phosphate may be linked to vascular function.en
dc.language.isoengen
dc.relation.ispartofseriesCanadian thesesen
dc.rightsThis publication is made available by the authority of the copyright owner solely for the purpose of private study and research and may not be copied or reproduced except as permitted by the copyright laws without written authority from the copyright owner.en
dc.subjectPhosphateen
dc.subjectCardiovascular diseaseen
dc.subjectEndotheliumen
dc.subjectEndothelial functionen
dc.titleThe role of acute phosphate supplementation in endothelium-dependent and -independent vasodilationen
dc.typethesisen
dc.description.degreeM.Sc.en
dc.contributor.supervisorPyke, Kyra E.en
dc.contributor.departmentKinesiology and Health Studiesen
dc.degree.grantorQueen's University at Kingstonen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record